Matches in DBpedia 2016-04 for { ?s ?p "Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi. The company was founded in Palo Alto, California in 1991 and went public in 1993.The company is working on an investigational Phase III drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma"@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Incyte abstract "Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi. The company was founded in Palo Alto, California in 1991 and went public in 1993.The company is working on an investigational Phase III drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma".
- Q6015591 abstract "Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi. The company was founded in Palo Alto, California in 1991 and went public in 1993.The company is working on an investigational Phase III drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma".